“It is our responsibility as an industry to help address the problem of escalating healthcare costs and to ensure those who need our medicines can access them.”
Giovanni Caforio is the CEO and Chairman of the Board of Bristol Myers Squibb (BMS). Caforio leads the company’s focus on researching and developing transformational medicines, which includes a leading portfolio of cancer immunotherapies. Under his leadership, BMS is evolving its operating model in order to increase speed and competitiveness.
Caforio has made significant contributions to improving BMS’s global strategic focus and operational performance. As the former Chief Operating Officer, Executive Vice President, and Chief Commercial Officer, he led the transformation of the fully integrated worldwide commercial organization and the companywide functions of enterprise services and global manufacturing and supply. He also helped establish BMS as a leader in immuno-oncology as President of US Pharmaceuticals and Senior Vice President of Global Oncology and Immunology.
Prior to joining BMS, he received his M.D. from the University of Rome and held research and marketing leadership roles at Abbott Laboratories. He is currently a member of the Board of Trustees of Hun School of Princeton, the Business Roundtable, CEO Roundtable on Cancer, the Pharmaceutical Research and Manufacturers of America (PhRMA), and The Prium.